Select Vaccines partner ships hep E kits to hotspot
Wednesday, 08 September, 2004
Select Vaccines' (ASX:SLT) licence partner Genelabs Diagnostics has provided the World Health Organisation with a "significant quantity" of the hepatitis E rapid diagnostic kits developed by Select, the company said today.
The kits, which were provided to the WHO on a humanitarian basis, will be used in the Darfur region of Sudan to help contain an outbreak of hepatitis E in the refugee camps. Select Vaccines licensed the hepatitis E rapid diagnostic kit, as well as a laboratory diagnostic to Genelabs for a 12-year term in August, in return for upfront payments and royalties.
Pancreatic cancer hijacks metabolism switch to help it spread
Pancreatic cancer hijacks a molecule known for regulating physiological processes, such as food...
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
